Implementation of diffusion-weighted magnetic resonance imaging in target delineation of central lung cancer accompanied with atelectasis in precision radiotherapy.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28927030)

Published in Oncol Lett on June 23, 2017

Authors

Xinli Zhang1,2, Zheng Fu1, Guanzhong Gong1, Hong Wei1, Jinghao Duan1, Zhaoqiu Chen1, Xiangming Chen2, Ruozheng Wang3, Yong Yin1

Author Affiliations

1: Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, Shandong 250117, P.R. China.
2: Department of Medical Oncology, Tai'an City Central Hospital, Tai'an, Shandong 271000, P.R. China.
3: Department of Radiation Oncology, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, P.R. China.

Articles cited by this

Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22

Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology (1988) 8.08

Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys (2000) 4.99

Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med (2003) 3.88

Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest (2007) 3.36

Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest (2003) 3.16

Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma. Radiother Oncol (2014) 2.08

Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. Radiology (1999) 1.88

Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol (2002) 1.52

A phase II comparative study of gross tumor volume definition with or without PET/CT fusion in dosimetric planning for non-small-cell lung cancer (NSCLC): primary analysis of Radiation Therapy Oncology Group (RTOG) 0515. Int J Radiat Oncol Biol Phys (2010) 1.26

Evaluation of a target contouring protocol for 3D conformal radiotherapy in non-small cell lung cancer. Radiother Oncol (1999) 1.20

2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. Ann Nucl Med (2007) 1.17

Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg (2000) 1.06

Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys (2009) 1.05

A study of prostate delineation referenced against a gold standard created from the visible human data. Radiother Oncol (2007) 1.03

Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg (2008) 0.95

Using diffusion-weighted MR imaging for tumor detection in the collapsed lung: a preliminary study. Eur Radiol (2008) 0.95

MRI simulation for radiotherapy treatment planning. Med Phys (2012) 0.95

MRI target delineation may reduce long-term toxicity after prostate radiotherapy. Acta Oncol (2013) 0.88

Differentiation of central lung tumor from postobstructive lobar collapse by rapid sequence computed tomography. J Thorac Imaging (1991) 0.86

Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers. Ann Thorac Surg (2011) 0.86

18F-FDG PET definition of gross tumor volume for radiotherapy of lung cancer: is the tumor uptake value-based approach appropriate for lymph node delineation? Int J Radiat Oncol Biol Phys (2010) 0.86

Critical review of PET-CT for radiotherapy planning in lung cancer. Crit Rev Oncol Hematol (2005) 0.84

Alterations in anatomic and functional imaging parameters with repeated FDG PET-CT and MRI during radiotherapy for head and neck cancer: a pilot study. BMC Cancer (2015) 0.83

Conformal radiotherapy for lung cancer: interobservers' variability in the definition of gross tumor volume between radiologists and radiotherapists. Radiat Oncol (2009) 0.83

Evaluation of patients with round atelectasis using 2-[18F]-fluoro-2-deoxy-D-glucose PET. J Comput Assist Tomogr (1998) 0.82

Guidelines for the role of FDG-PET/CT in lung cancer management. J Infect Public Health (2012) 0.82

PET and PET-CT in radiation treatment planning for lung cancer. Expert Rev Anticancer Ther (2010) 0.79

[Optimization of radiotherapy planning for non-small cell lung cancer (NSCLC) using 18FDG-PET]. Nuklearmedizin (2002) 0.78

Differentiation of central lung cancer from atelectasis: comparison of diffusion-weighted MRI with PET/CT. PLoS One (2013) 0.77

Converting from CT- to MRI-only-based target definition in radiotherapy of localized prostate cancer: A comparison between two modalities. Strahlenther Onkol (2015) 0.76

Intrapatient comparison of 2-deoxy-2-[F-18]fluoro-D-glucose with positron emissiontomography/computed tomography to Tc-99m fanolesomab (NeutroSpec) for localization of infection. Mol Imaging Biol (2007) 0.76